Full Press Release Details
Ivy Brain Tumor Center And BridgeBio Subsidiary QED Therapeutics Announce Collaboration To Advance Cancer Research And Treatment Options.
BBIO
Ivy Brain Tumor Center And BridgeBio Subsidiary QED Therapeutics Announce Collaboration To Advance Cancer Research And Treatment Options
Key Takeaway: Ivy Brain Tumor Center And BridgeBio Subsidiary QED Therapeutics Announce Collaboration To Advance Cancer Research And Treatment Options
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis